TQB2922 not checked

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
5 active
5 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“TQB2922 is an anti-EGFR/c-Met bispecific antibody, subtype Immunoglobulin G1 (IgG1). TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus preventing tumour growth and progression. At the same time, TQB2922 can target EGFR and c-Met on the surface of tumour cells through antibody-dependent cytotoxicity (ADCC) and…”In the company’s words, NCT07044908 on ClinicalTrials.gov
Tested for
RAS/BRAF Wild Type Colorectal Cancer, Colorectal Neoplasms, Recurrent/Metastatic Head and Neck Cancer, Advanced Cancer, Advanced Cancers
Main trialPhase 1/2
“This is a multicenter, open Phase Ib/II clinical study evaluating the safety and efficacy of TQB2922 in combination with TAS-102±bevacizumab in subjects with RAS/BRAF wild-type unresectable locally advanced or metastatic colorectal cancer that has failed treatment with oxaliplatin, fluorouracil-based and irinotecan.”In the company’s words, NCT07044908 on ClinicalTrials.gov

Other drugs for Colorectal Neoplasms

All 392 drugs for Colorectal Neoplasms

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting Jul 2026 TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
Phase 1/2Not yet recruiting 31 Aug 2027 TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread
Phase 1/2Not yet recruiting Feb 2029 Treatment of Recurrent/Metastatic Head and Neck Cancer
Phase 1Recruiting Dec 2026 Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers
Phase 1Recruiting Dec 2029 Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow TQB2922

Following is part of Solo: you see every change to TQB2922 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in